Cagrisema 5 mg

CagriSema Peptide for Sale: Research-Grade Cagrilintide + Semaglutide Combination

Researchers studying next-generation obesity pharmacotherapy need access to the combination that produced 22.7% mean weight reduction in the REDEFINE-1 Phase 3 trial. The cagrisema peptide combination pairs cagrilintide, a long-acting amylin analog, with semaglutide, the established GLP-1 receptor agonist, in a fixed-dose formulation. Pure Peptide Factory now offers this research combination in a single vial, shipped domestically with full batch documentation and cold-chain integrity.

When you buy cagrisema peptide for your laboratory, you receive a precisely formulated blend that mirrors the clinical trial ratio. This allows researchers to study the additive mechanisms of amylin and GLP-1 receptor co-activation without sourcing and mixing two separate compounds. Furthermore, our domestic supply chain and quality verification process ensure that your research data remains consistent across study arms.

Why Researchers Choose Pure Peptide Factory for CagriSema Peptide

Pre-Formulated Clinical Trial Ratio

The CagriSema clinical program uses a fixed-dose combination of cagrilintide 2.4mg and semaglutide 2.4mg. We replicate this exact ratio in our research vials, so you no longer need to purchase separate cagrilintide and semaglutide products and mix them manually. As a result, your combination protocol eliminates concentration errors and batch variability from two separate compounds.

Lot-Specific Documentation Covering Both Peptides

Each cagrisema peptide vial ships with an HPLC chromatogram and mass spectrometry report that verifies the presence and purity of both components. Specifically, we confirm the molecular weight targets for cagrilintide (~4291 g/mol) and semaglutide (~4113 g/mol) in the same analysis. Consequently, your compliance office receives a single Certificate of Analysis covering the entire combination product.

Domestic Cold-Chain You Can Trust

Shipping a dual-peptide combination requires careful temperature management. Therefore, we store all cagrisema peptide inventory domestically and ship using phase-change cooling rated for 96-hour protection. Most orders arrive within 1 to 3 business days.

Run Comparison Studies Without Sourcing Headaches

Many protocols compare the cagrisema combination against semaglutide monotherapy, tirzepatide, or cagrilintide alone. Because we stock all four compounds in the same cold-storage facility, your comparison data remains free of supplier variability.

What Is CagriSema Peptide?

Novo Nordisk’s Fixed-Dose Obesity Combination

CagriSema is the investigational fixed-dose combination of cagrilintide (AM833), a long-acting amylin receptor analog, and semaglutide, the established GLP-1 receptor agonist. Specifically, the clinical formulation combines 2.4mg of each peptide in a single once-weekly subcutaneous injection. The REDEFINE Phase 3 program is evaluating this combination across obesity, type 2 diabetes, MASH, and cardiovascular outcomes.

In the landmark REDEFINE-1 trial (NEJM, June 2025), 3,417 participants received either CagriSema, cagrilintide monotherapy, semaglutide monotherapy, or placebo. The cagrisema peptide arm produced a mean weight reduction of 22.7% at 68 weeks, compared to 12.1% for cagrilintide alone, 15.7% for semaglutide alone, and 3.0% for placebo. This additive effect is exactly what researchers are now studying at the preclinical level.

Mechanism: Why Amylin + GLP-1 Produces Additive Effects

Semaglutide activates GLP-1 receptors on pancreatic beta cells and hypothalamic appetite circuits. Cagrilintide activates amylin receptors (AMY1R, AMY2R, AMY3R) in the brainstem area postrema and dorsal vagal complex. These two receptor systems operate in parallel, not in competition. Specifically, GLP-1 receptor activation reduces food intake through POMC neuron activation in the arcuate nucleus, while amylin receptor activation slows gastric emptying and directly suppresses appetite through brainstem satiety pathways. Consequently, the combined receptor activation produces weight loss greater than either mechanism alone.

This mechanistic complementarity is the reason cagrisema peptide is a critical research tool for laboratories investigating dual-mechanism obesity pharmacology.

CagriSema Peptide Research Applications

Obesity and Weight Management Research

The primary application for this combination is preclinical obesity research. Published data from diet-induced obesity (DIO) mouse models shows that the amylin + GLP-1 combination produces approximately 18–22% weight reduction, surpassing either agent alone. Furthermore, researchers examine body composition changes, food intake patterns, and energy expenditure to isolate how the two mechanisms interact.

Head-to-Head Comparison Studies

With the cagrisema peptide combination, your lab can run direct comparison protocols against semaglutide monotherapy, cagrilintide monotherapy, tirzepatide, or retatrutide. This is the research that mirrors the clinical trial landscape, making your preclinical findings directly relevant to ongoing drug development.

Glycemic Control and Type 2 Diabetes

Cagrilintide suppresses postprandial glucagon, while semaglutide enhances glucose-dependent insulin secretion. Therefore, the combination addresses both alpha-cell and beta-cell dysfunction in diabetic models. Researchers use the cagrisema peptide to measure HbA1c changes, insulin sensitivity improvements, and beta-cell preservation in T2DM rodent models.

MASH and Hepatic Fibrosis

The REDEFINE program includes MASH cohorts, and preclinical research on the combination’s effects on liver fat, fibrosis stage, and inflammatory markers is expanding. The cagrisema peptide provides the translational tool to study how dual amylin/GLP-1 receptor activation affects hepatic outcomes.

CagriSema Dosage Chart for Research Protocols

The following dosage reference is compiled from the REDEFINE Phase 3 trial and published preclinical studies. It is strictly for laboratory research design. We do not provide human dosing recommendations.

Research Model	Dose (Cagrilintide + Semaglutide)	Route	Frequency	Reference
REDEFINE-1 clinical (human, weeks 17+)	2.4 mg + 2.4 mg	SC	Once weekly	NEJM 2025
Dose escalation (clinical, weeks 1-16)	0.25 mg through 2.4 mg	SC	Weekly step-up	REDEFINE protocol
Rodent DIO model	0.1–0.5 mg/kg each	SC or IP	Every 3–5 days	Multiple
Combination vs. monotherapy protocols	Equivalent dose of cagrisema peptide vs. semaglutide alone	SC	Weekly	Institutional protocols
Cell culture receptor assays	Nanomolar concentrations	In vitro	Per assay	Multiple

For researchers seeking a convenient reference, this cagrisema dosage chart can be printed or downloaded for lab use. Additionally, we encourage investigators to consult the REDEFINE-1 supplementary appendix for full escalation details.

CagriSema vs Tirzepatide: What Researchers Need to Know

The most common comparison question in the field is how the cagrisema peptide combination stacks up against tirzepatide. Both are multi-mechanism obesity agents, but they operate through different receptor combinations:

Feature	CagriSema	Tirzepatide
Mechanism	Amylin receptor + GLP-1 receptor	GIP receptor + GLP-1 receptor
Components	Cagrilintide 2.4 mg + Semaglutide 2.4 mg	Single molecule (tirzepatide)
Phase 3 weight loss	22.7% (REDEFINE-1)	22.5% (SURMOUNT-1)
FDA approval	Not yet approved (Phase 3)	Approved (Mounjaro/Zepbound)
Dosing frequency	Once weekly	Once weekly
Receptor novelty	Amylin pathway is new to obesity	GIP pathway was previously underappreciated
Best for studying	Amylin + GLP-1 synergy	GIP + GLP-1 synergy

For comparative research, the cagrisema peptide provides the amylin receptor dimension that tirzepatide lacks. Therefore, your protocol design should consider which mechanism you aim to dissect. Our facility stocks both tirzepatide and the cagrisema combination for side-by-side investigation.

CagriSema Side Effects and Safety Profile

Published clinical data from the REDEFINE program indicates that the side effect profile of the cagrisema combination mirrors the known profiles of its components. Specifically, gastrointestinal events (nausea, vomiting, diarrhea, constipation) were the most common adverse effects, consistent with both GLP-1 and amylin receptor agonism. These effects were predominantly mild to moderate and decreased over time. Furthermore, no unexpected safety signals emerged in the 3,417-participant Phase 3 trial. As with all research peptides, institutional biosafety protocols must be followed for any in vivo work.

How to Reconstitute CagriSema Peptide

1. Sanitize the vial stopper with 70% isopropyl alcohol.
2. Inject bacteriostatic water slowly against the vial wall. Because the vial contains a fixed-dose blend of two peptides, avoid directing the stream at the lyophilized cake.
3. Allow the powder to dissolve without agitation for 3 to 5 minutes.
4. Gently swirl until the solution is clear. Do not shake.
5. Verify a clear, colorless solution before use.

Concentration Reference (2.4 mg/2.4 mg vial):

• 2.4mg cagrilintide + 2.4mg semaglutide + 1mL water = 4.8mg/mL total peptide
• Adjust reconstitution volume according to your research model’s required dose.

Storage:

• Lyophilized powder: 24 months at -20°C.
• Reconstituted solution: 28 days at 2–8°C. Do not freeze.

Product Specifications

Available Configuration

CagriSema peptide is available in vials containing 2.4mg cagrilintide + 2.4mg semaglutide. This fixed-dose combination matches the REDEFINE-1 clinical trial ratio.

Quality Verification

• • Purity: 98% minimum per component (HPLC verified)
  • Identity: Mass spectrometry confirmed for both cagrilintide and semaglutide
  • Endotoxin: Less than 0.1 EU/mL

• Sterility: Verified per USP 71
• Current Batch: #PPF-CS-0426 | Purity: 98.6% — Download: HPLC Certificate | MS Report

Frequently Asked Questions

What is cagrisema peptide?

CagriSema is the investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). Specifically, the clinical formulation uses 2.4mg of each peptide. The combination produced 22.7% mean weight reduction in the REDEFINE-1 Phase 3 trial.

Where can I buy cagrisema peptide for research?

Pure Peptide Factory stocks the research-grade combination domestically. Orders ship same-day with cold-chain packaging and full HPLC/MS documentation.

How does cagrisema compare to tirzepatide?

CagriSema combines amylin and GLP-1 receptor activation, while tirzepatide combines GIP and GLP-1. Both produce approximately 22.5–22.7% weight loss in Phase 3 trials, but through different mechanisms. See the comparison table above for full details.

What is the cagrisema dosage used in research?

The clinical dose is cagrilintide 2.4mg + semaglutide 2.4mg once weekly. Preclinical rodent studies use bodyweight-adjusted doses. Refer to the cagrisema dosage chart above for research model-specific references.

Is cagrisema FDA approved?

No. CagriSema is currently in Phase 3 development and is not yet approved for any indication. Our research-grade peptide is strictly for laboratory use.

What are the side effects of cagrisema?

Clinical trials revealed predominantly gastrointestinal side effects (nausea, vomiting, diarrhea), which were generally mild and transient. No serious safety concerns emerged in Phase 3.

Can I buy cagrisema without a prescription?

Yes, for laboratory research under research-use-only terms. This is not a prescription medication.

Order CagriSema Peptide for Research

Secure Checkout

• Credit card, cryptocurrency, or wire transfer
• Same-day dispatch for orders placed before 2 PM EST
• Cold-chain packaging with phase-change cooling
• Discreet labeling with full tracking

Institutional Accounts

Net-30 terms and purchase orders accepted for universities and research institutions. Contact us for bulk pricing on 50 vials or more.

Add to cart and get the research-grade cagrisema peptide combination that mirrors the REDEFINE-1 clinical trial formulation.